although
mammographi
gold
standard
breast
cancer
screen
high
rate
falseposit
mammogram
remain
concern
thu
unmet
clinic
need
noninvas
reliabl
test
differenti
malign
benign
breast
lesion
order
avoid
subject
patient
abnorm
mammogram
unnecessari
followup
diagnost
procedur
serum
sampl
malign
breast
lesion
benign
breast
lesion
comprehens
profil
microrna
mirna
use
nextgener
sequenc
sampl
profil
three
outlier
remov
base
princip
compon
analysi
pca
remain
sampl
divid
train
n
test
n
set
ratio
analysi
train
set
significantli
differenti
express
mirna
adjust
p
identifi
correct
multipl
test
use
fals
discoveri
rate
subsequ
predict
classif
model
use
eightmirna
signatur
bayesian
logist
regress
algorithm
develop
base
receiv
oper
characterist
roc
curv
analysi
test
set
model
could
achiev
area
curv
auc
togeth
studi
demonstr
potenti
use
circul
mirna
adjunct
test
stratifi
breast
lesion
patient
abnorm
screen
mammogram
mammographi
current
gold
standard
breast
cancer
screen
howev
modal
produc
falseneg
also
high
falseposit
rate
accord
studi
unit
state
us
screen
mammogram
n
approxim
n
found
abnorm
women
diagnos
ductal
carcinoma
situ
dci
invas
breast
cancer
henc
women
abnorm
mammogram
breast
cancer
diagnosi
remain
women
unnecessarili
recal
addit
diagnost
imag
test
andor
tissu
biopsi
invas
expens
timeconsum
stressinduc
furthermor
individu
woman
may
undergo
sever
breast
screen
lifetim
cumul
probabl
falseposit
recal
year
annual
mammogram
screen
estim
falseposit
mammogram
also
impact
economi
impos
exorbit
econom
burden
instanc
nation
expenditur
falseposit
mammogram
us
includ
variou
servic
cost
fee
followup
diagnost
procedur
estim
us
billion
annual
base
assumpt
falseposit
rate
among
million
women
age
year
unmet
clinic
need
noninvas
quick
afford
reliabl
test
differenti
malign
benign
breast
lesion
order
avoid
subject
patient
abnorm
mammogram
unnecessari
followup
diagnost
procedur
liquid
biopsi
util
biomark
bodi
fluid
deem
promis
detect
method
howev
current
bloodbas
biomark
earli
detect
breast
cancer
stratif
differenti
diagnosi
breast
lesion
cancer
antigen
cancer
antigen
carcinoembryon
antigen
cea
blood
tumor
marker
breast
cancer
recommend
european
group
tumor
marker
egtm
american
societi
clinic
oncolog
asco
guidelin
purpos
due
lack
sensit
insuffici
evid
role
earlystag
breast
cancer
manag
last
decad
variou
effort
made
discov
circul
biomark
breast
cancer
includ
microrna
mirna
mirna
evolutionari
conserv
singlestrand
noncod
rna
nucleotid
primari
function
mediat
degrad
translat
repress
mrna
target
apart
critic
role
normal
physiolog
state
dysregul
mirna
also
associ
hallmark
cancer
tumor
suppressor
oncogen
activ
aberr
express
mirna
demonstr
varieti
malign
circul
mirna
propos
clinic
use
biomark
due
express
level
chang
associ
cancer
develop
also
attribut
stabil
differ
bodi
fluid
sourc
extrem
condit
eg
rnase
digest
multipl
freezethaw
cycl
prolong
storag
period
henc
studi
aim
identifi
mirna
signatur
high
discrimin
abil
malign
benign
breast
lesion
approach
util
nextgener
sequenc
ng
mirna
transcript
follow
identif
significantli
differenti
express
mirna
develop
mirnabas
classif
model
malign
breast
lesion
train
set
total
sampl
compris
malign
case
benign
control
test
set
sampl
malign
case
benign
control
train
test
set
compris
variou
race
includ
chines
malay
indian
other
median
age
sampl
train
test
set
year
respect
malign
case
train
test
set
similar
histolog
type
receptor
statu
tumor
size
tumor
grade
lymph
node
statu
tabl
likewis
train
test
set
benign
breast
lesion
similar
characterist
tabl
benign
lesion
one
histolog
patholog
eg
atyp
ductal
hyperplasia
adh
fibroadenoma
fa
count
tabl
comprehens
profil
mirna
carri
employ
htg
edgeseq
mirna
whole
transcriptom
assay
cohort
subject
compris
malign
case
benign
control
three
outlier
malign
case
benign
control
exclud
dataset
base
princip
compon
analysi
pca
figur
order
limit
skew
dataset
would
otherwis
lead
bias
data
analysi
mislead
analysi
outcom
remain
sampl
randomli
divid
train
n
test
n
set
use
train
set
eight
train
subset
gener
differenti
express
analysi
perform
train
subset
follow
analysi
differ
number
significantli
differenti
express
mirna
rang
mirna
absolut
log
fold
chang
fals
discoveri
rate
fdr
obtain
eight
train
subset
data
shown
significantli
differenti
express
mirna
eight
mirna
consist
found
eight
train
subset
train
set
eight
mirna
significantli
upregul
malign
case
compar
benign
control
p
tabl
figur
next
pca
eight
significantli
differenti
express
mirna
use
visual
discrimin
level
malign
case
benign
control
clear
separ
observ
malign
case
benign
control
figur
bayesian
logist
regress
model
creat
use
eight
mirna
discov
train
set
train
model
yield
area
curv
auc
base
roc
curv
analysi
recal
precis
balanc
accuraci
respect
figur
tabl
model
test
use
independ
test
set
result
auc
recal
precis
balanc
accuraci
respect
figur
tabl
subject
test
set
correctli
classifi
four
misclassifi
among
misclassifi
subject
two
falseneg
dci
two
falseposit
one
fa
wherea
anoth
fibrocyst
chang
residu
lobular
carcinoma
situ
lci
present
studi
describ
identif
circul
eightmirna
signatur
significantli
differenti
express
malign
breast
lesion
case
benign
breast
lesion
control
could
segreg
case
control
pca
addit
model
show
high
precis
recal
balanc
accuraci
valu
togeth
present
find
demonstr
use
circul
mirna
blood
promis
tool
detect
breast
cancer
higher
auc
discrimin
malign
case
benign
control
compar
previou
mirna
discoveri
studi
mirna
biomark
signatur
auc
recal
precis
balanc
accuraci
respect
potenti
develop
blood
test
stratif
breast
lesion
blood
test
could
incorpor
diagnosticclin
workflow
ie
initi
screen
mammographi
diagnost
imag
assess
tissu
biopsi
aim
assist
clinician
decis
make
exampl
neg
test
result
could
potenti
indic
initi
screen
mammogram
falseposit
henc
diagnost
imag
procedur
tissu
biopsi
would
warrant
contrast
posit
test
result
would
lead
addit
diagnost
imag
andor
tissu
biopsi
perform
order
confirm
presenc
absenc
malign
breast
lesion
wide
rang
bloodbas
biomark
candid
includ
dna
rna
protein
methyl
lipid
metabolit
report
literatur
show
notabl
potenti
breast
cancer
detect
key
studi
cancerseek
grail
circul
cellfre
genom
atla
ccga
project
employ
circul
dna
cancer
marker
although
circul
dnabas
blood
test
abl
identifi
multipl
cancer
sensit
discrimin
breast
cancer
healthi
noncanc
control
remain
poor
ie
cancerseek
ccga
besid
test
less
sensit
detect
breast
cancer
earli
stage
compar
late
stage
potenti
biomark
differenti
breast
cancer
benign
breast
lesion
includ
protein
biomark
combin
epitheli
membran
antigen
ema
auc
development
endotheli
auc
discrimin
abil
individu
methyl
promot
adenomat
polyposi
coli
apc
retino
acid
receptor
classifi
malign
nonmalign
control
yield
auc
outperform
tradit
tumor
marker
cea
identifi
lowgrad
tumor
earlystag
tripleneg
breast
cancer
addit
signific
mirna
biomark
candid
publish
studi
shimomura
et
al
largest
breast
cancer
mirna
discoveri
date
report
fivemirna
could
recogn
breast
cancer
case
noncanc
control
auc
nevertheless
downsid
studi
biomark
signatur
profil
develop
use
microarraybas
platform
known
poor
specif
one
five
mirna
could
valid
serum
sampl
qrtpcr
anoth
studi
effici
artifici
neural
network
ann
develop
identifi
malign
breast
lesion
women
breast
imag
report
data
system
birad
mammographi
follow
screen
n
valid
n
test
phase
n
shown
ann
could
discrimin
birad
breast
lesion
malign
benign
use
plasma
level
auc
recent
studi
use
qrtpcr
serum
identifi
individu
marker
distinguish
breast
cancer
case
n
patient
benign
breast
lesion
n
healthi
individu
n
auc
respect
howev
find
yet
valid
besid
mirna
new
signatur
deriv
metabolit
lipid
capabl
discrimin
malign
benign
breast
lesion
emerg
note
present
studi
mirna
signatur
show
compar
auc
abovement
studi
eight
mirna
identifi
present
signatur
compris
upregul
malign
breast
lesion
compar
benign
breast
lesion
role
mirna
wide
character
requir
elucid
due
limit
public
literatur
eight
mirna
associ
breast
cancer
identifi
one
mirna
involv
breast
cancer
develop
regul
ctermin
bind
protein
metabol
syndrom
besid
suggest
play
tumor
suppressor
role
especi
estrogen
receptor
er
neg
basallik
tumor
low
express
breast
cancer
tissu
associ
poor
prognosi
howev
present
studi
upregul
express
observ
case
malign
breast
lesion
shown
overexpress
breast
cancer
cell
line
suppress
cell
migrat
prolifer
epithelialmesenchym
transit
furthermor
axi
involv
long
noncod
rna
breast
cancer
progress
apart
breast
cancer
alongsid
implic
malign
upregul
promot
glioma
cell
prolifer
downregul
express
key
regul
signal
pathway
adenomat
polyposi
coli
colorect
cancer
may
present
novel
therapeut
candid
base
inhibitori
action
tumor
growth
metastasi
angiogenesi
target
vascular
endotheli
growth
factor
vegfa
high
mobil
group
athook
furthermor
one
eight
mirna
propos
use
predictor
postop
outcom
patient
small
cell
carcinoma
esophagu
due
signific
correl
tumor
relaps
howev
result
valid
six
sampl
use
studythre
case
rapid
tumor
relaps
three
case
longterm
surviv
addit
involv
also
describ
liver
cancer
base
two
independ
studi
first
studi
report
downregul
express
tumor
tissu
wherea
second
studi
observ
elev
level
hepatocellular
carcinoma
tissu
patient
correl
poorer
prognosi
may
act
tumor
suppressor
identifi
potenti
prognost
biomark
colorect
cancer
decreas
level
serum
exosom
report
associ
poor
surviv
period
among
colorect
cancer
patient
addit
associ
cervic
prostat
cancer
report
patient
earlystag
cervic
squamou
cell
carcinoma
member
sixmirna
panel
abl
predict
lymph
node
metastasi
auc
prostat
cancer
probabl
role
mechan
underlin
increas
prostat
cancer
risk
kallikreinrel
peptidas
mirsnp
tallel
demonstr
furthermor
recent
studi
increas
express
prostat
tumor
tissu
associ
higher
gleason
grade
thu
indic
possibl
use
stratifi
patient
risk
develop
aggress
prostat
cancer
although
previous
report
involv
cancer
aberr
express
mirna
plasma
sampl
detect
patient
condit
heart
failur
glaucoma
epilepsi
hand
identifi
one
mirna
candid
antivir
therapeut
middl
east
respiratori
syndrom
mer
base
comput
approach
use
bioinformat
tool
wherea
inform
diseas
associ
report
literatur
despit
plethora
potenti
breast
cancer
biomark
describ
literatur
none
proceed
clinic
trial
enhanc
translat
current
find
actual
clinic
practic
sever
gap
limit
prior
studi
taken
consider
address
present
studi
best
knowledg
comprehens
mirna
profil
breast
cancer
conduct
thu
far
total
malign
benign
breast
lesion
screen
express
mirna
transcript
date
cancer
studi
deploy
ng
tool
circul
mirna
biomark
discoveri
none
report
breast
cancer
ng
chosen
profil
platform
studi
due
highthroughput
capabl
superior
detect
sensit
compar
method
microarray
realtim
qrtpcr
besid
present
work
biomark
discoveri
studi
breast
cancer
util
multiraci
multicent
asian
cohort
preoper
serum
blood
sampl
prospect
collect
women
abnorm
mammogram
ensur
minim
effect
confound
factor
technic
bias
data
analysi
preanalyt
factor
standard
term
sampl
collect
handl
process
storag
furthermor
train
test
set
encompass
independ
studi
cohort
prevent
overfit
machin
learn
nonetheless
limit
present
studi
firstli
although
present
mirna
signatur
show
promis
discrimin
malign
benign
breast
lesion
still
need
valid
result
independ
cohort
case
control
welldocu
previou
breast
cancer
circul
mirna
biomark
studi
publish
independ
investig
show
inconsist
result
lack
overlap
find
inconsist
could
attribut
technic
bias
constraint
studi
design
failur
properli
assess
account
individu
environment
factor
data
analysi
addit
valid
studi
prospect
cohort
studi
blind
studi
also
warrant
examin
clinic
valid
present
mirna
signatur
benchmark
exist
imag
modal
prospect
cohort
studi
clinic
util
mirna
signatur
also
determin
compar
diagnost
outcom
result
use
mirna
signatur
outcom
result
use
addit
sensit
specif
mirna
signatur
also
test
blood
sampl
obtain
ethnic
popul
caucasian
well
blood
sampl
subject
cancer
type
secondli
model
misclassifi
four
benign
breast
lesion
two
dci
case
misclassifi
benign
lesion
wherea
two
benign
control
one
fa
anoth
fibrocyst
chang
lci
misclassifi
malign
lesion
misclassif
could
due
underli
biolog
similar
malign
benign
lesion
two
subject
benign
lesion
could
monitor
close
determin
develop
breast
cancer
futur
thirdli
plausibl
comorbid
medic
taken
subject
could
affect
express
level
circul
mirna
numer
circul
mirna
biomark
studi
lack
adjust
factor
henc
futur
research
adequ
consider
given
account
adjust
possibl
effect
comorbid
medic
express
circul
mirna
biomark
togeth
present
studi
highlight
discoveri
eightmirna
signatur
novel
circul
biomark
breast
cancer
base
mirna
signatur
gener
classif
model
high
discrimin
abil
classifi
malign
benign
breast
lesion
auc
present
mirna
signatur
may
potenti
develop
adjunct
test
stratifi
breast
lesion
patient
abnorm
screen
mammogram
aim
reduc
number
patient
falseposit
mammogram
subject
unwarr
tissu
biopsi
futur
investig
addit
cohort
prospect
blind
studi
carri
ascertain
clinic
valid
clinic
util
mirna
signatur
subject
studi
initi
abnorm
screen
mammogram
evalu
diagnost
imag
test
conduct
specialist
radiologist
refer
tissu
biopsi
subject
studi
includ
patient
benign
lesion
calcif
discharg
follow
addit
diagnost
imag
test
preoper
peripher
blood
sampl
prospect
collect
women
abnorm
mammogram
nation
cancer
centr
singapor
singapor
singapor
tan
tock
seng
hospit
singapor
singapor
year
addit
serum
sampl
also
obtain
singhealth
tissu
repositori
singapor
singapor
women
invas
ductallobularmucinouspapillari
carcinoma
dci
benign
breast
lesion
studi
women
invas
carcinoma
dci
defin
malign
case
wherea
women
benign
breast
lesion
defin
benign
control
written
inform
consent
obtain
particip
studi
ethic
approv
studi
obtain
central
institut
review
board
cirb
singhealth
cirb
refer
number
blood
sampl
collect
prior
surgeri
blood
sampl
collect
bd
vacutain
sst
tube
becton
dickinson
compani
franklin
lake
nj
usa
centrifug
rcf
min
room
temperatur
within
min
venipunctur
serum
sampl
store
aliquot
c
use
serum
sampl
without
hemolysi
use
serum
sampl
thaw
ice
sampl
prepar
accord
htg
edgeseq
mirna
whole
transcriptom
assay
htg
molecular
diagnost
inc
tucson
az
usa
protocol
htg
molecular
diagnost
inc
purifi
pcr
product
obtain
accord
manufactur
protocol
subsequ
use
sequenc
human
brain
refer
rna
sampl
ambion
austin
tx
usa
process
serv
control
librari
sequenc
illumina
nextseq
platform
illumina
san
diego
ca
usa
use
high
output
kit
cycl
two
index
read
illumina
phix
spike
librari
data
sequenc
obtain
demultiplex
fastq
file
htg
edgeseq
parser
use
align
fastq
file
mirna
refer
sequenc
obtain
databas
raw
data
count
sequenc
correspond
mirna
gener
normal
use
median
ratio
method
tool
version
pca
perform
sampl
use
mirna
detect
outlier
dataset
figur
remov
three
outlier
base
pca
sampl
randomli
proport
divid
train
n
malign
case
benign
control
test
n
malign
case
benign
control
set
estim
ratio
figur
mirna
select
train
set
use
purpos
identifi
mirna
could
discrimin
malign
case
benign
control
train
set
eight
train
subset
gener
train
subset
compris
differ
sampl
size
rang
total
number
sampl
train
set
respect
select
sampl
train
subset
random
train
subset
differenti
express
analysi
perform
use
tool
version
significantli
differenti
express
mirna
defin
mirna
absolut
log
fold
chang
fdr
malign
case
versu
benign
control
reason
perform
analysi
eight
train
subset
separ
identifi
significantli
differenti
express
mirna
common
eight
train
subset
order
elimin
influenc
sampl
size
select
mirna
analysi
develop
classif
model
malign
benign
breast
lesion
mirna
signatur
compris
significantli
differenti
express
mirna
identifi
train
set
use
input
variabl
statist
algorithm
unsupervis
cluster
base
pca
perform
use
mirna
signatur
first
two
princip
compon
use
visual
cluster
malign
case
benign
control
order
develop
supervisedlearn
model
use
train
set
repeat
kfold
cross
valid
techniqu
k
repeat
five
time
bayesian
logist
regress
algorithm
appli
perform
classif
model
built
use
train
set
evalu
use
independ
test
set
base
differ
evalu
metric
includ
specif
sensit
auc
roc
curv
addit
recal
precis
metric
also
estim
due
imbalanc
proport
malign
case
benign
control
statist
machinelearn
analysi
carri
use
r
softwar
version
r
caret
packag
version
use
train
develop
test
perform
model
wherea
roc
curv
gener
use
r
proc
packag
version
present
studi
report
discoveri
serumderiv
eightmirna
signatur
compris
novel
circul
biomark
signatur
show
promis
discrimin
malign
benign
breast
lesion
among
women
abnorm
screen
mammogram
current
find
suggest
possibl
use
circul
mirna
adjunct
test
stratif
breast
lesion
potenti
reduc
number
unwarr
tissu
biopsi
among
abnorm
screen
mammogram
